Evicel market seen growing on surgical demand and bleeding disorder cases
The Business Research Company says the Evicel market is set for long-term growth through 2035, driven by rising surgical volumes, more bleeding disorders and wider use of hemostatic agents. North America led in 2025, while Asia-Pacific is expected to be the fastest-growing region.
Why it matters: - Evicel is a fibrin sealant used to control bleeding during surgery, so demand tracks with broader surgery volumes and the need for safer, faster hemostasis. - The market outlook points to steady demand in procedures where blood loss control affects patient outcomes, recovery time and surgical efficiency. - Growth in this market also reflects wider adoption of plasma-derived and biocompatible surgical products.
What happened: - The Business Research Company released its Evicel Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the Evicel market has expanded historically because of bleeding risks in surgery, limits of mechanical bleeding control, wider acceptance of plasma-derived products, more complex procedures and a stronger focus on patient safety. - The report forecasts continued growth through 2035 as minimally invasive surgeries become more common, surgical volumes rise, specialty clinics expand, biomaterial innovation advances and surgical efficiency remains a priority. - The report identifies North America as the largest Evicel market in 2025. - The report projects Asia-Pacific as the fastest-growing region during the forecast period. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The company also promoted a free sample of the market report and the full report.
The details: - Evicel is made from human fibrinogen and thrombin. - The product helps promote clot formation during surgery and supports healing. - Common use cases include cardiovascular, liver and orthopedic procedures. - The sealant’s biological compatibility lowers the risk of adverse reactions, which makes it useful where precise bleeding control is needed. - Rising bleeding disorders are a major driver of demand. - These disorders reduce the blood’s ability to clot and can lead to excessive or prolonged bleeding after injury or surgery. - Genetic conditions such as hemophilia, poor nutrition, obesity and liver disorders are contributing to the rise in bleeding disorders. - Pfizer said in May 2025 that the haemophilia A and B patient population in the UK exceeded 11,800 in 2023/2024. - Chronic diseases are also expanding the addressable market. - Diabetes and heart disease can affect healing and clotting, increasing the need for surgical hemostats. - The UK’s Office for Health Improvement & Disparities reported in March 2024 that diabetes care outcomes improved between 2022 and 2023. - That data included a 22% increase in type 1 diabetes patients receiving all recommended care processes and a 21% rise for type 2 diabetes patients. - Demand is also rising with the growth of aesthetic surgery. - The International Society of Aesthetic Plastic Surgery said in June 2024 that total aesthetic procedures rose 3.4% in 2023 to 34.9 million. - Face and head procedures grew by nearly 20% to more than 6.5 million cases. - The report highlights growing use of fibrin sealants during surgery, demand for biocompatible hemostatic agents, more cardiovascular and liver operations, preference for human plasma-based sealants and broader use of advanced surgical techniques.
Between the lines: - The market story is less about one drug and more about a structural shift toward surgical products that reduce complications and support faster recovery. - The report’s growth drivers suggest demand is coming from both essential care and elective procedures, which can broaden the market base. - North America's lead likely reflects mature healthcare adoption, while Asia-Pacific growth points to faster expansion where surgical volumes and healthcare access are rising.
What's next: - The Business Research Company says its 2026 reports include market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspot infographics and updated graphics. - The report's forecast through 2035 suggests continued opportunity for suppliers of hemostatic agents tied to surgery growth and clinical demand.
The bottom line: - Evicel's market trajectory is tied to more surgery, more bleeding-risk patients and continued preference for biologic hemostatic products.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Africa News Guide
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.